Back to Search
Start Over
Anti-Vascular Endothelial Growth Factor Treatment for Macular Edema in Eyes with Branch Retinal Vein Occlusion with vs Without Glaucoma – Does Glaucoma Affect Visual Outcome in Eyes with BRVO-ME After antiVEGF Injections?
- Source :
- Clinical Ophthalmology, Vol Volume 16, Pp 2275-2283 (2022)
- Publication Year :
- 2022
- Publisher :
- Dove Medical Press, 2022.
-
Abstract
- Shin Asami, Masahiko Sugimoto, Hideyuki Tsukitome, Kumiko Kato, Hisashi Matsubara, Mineo Kondo Department of Ophthalmology, Mie University Graduate School of Medicine, Tsu, Mie, JapanCorrespondence: Masahiko Sugimoto, Department of Ophthalmology, Mie University Graduate School of Medicine, 2-174 Edobashi, Tsu, Mie, 514-8507, Japan, Tel +81-59-231-5027, Fax +81-59-231-3036, Email sugmochi@clin.medic.mie-u.ac.jpPurpose: To compare the therapeutic effects of anti-vascular endothelial growth factor (anti-VEGF) agents in eyes with macular edema associated with branch retinal vein occlusion (BRVO-ME) with glaucoma to those without glaucoma.Patients and Methods: This retrospective study was conducted using the medical records of Mie University Hospital from 2013 to 2017. Patients were recruited if they had received anti-VEGF agents for BRVO-ME treatment and included 30 patients (30 eyes) without glaucoma (G[-] group) and 27 patients (27 eyes) with glaucoma (G[+] group). The central retinal thickness (CRT) and best-corrected visual acuity (BCVA) at 3 months after a single injection of anti-VEGF agents were compared between the two groups.Results: Before treatment, the mean±standard deviation of the CRT was 514.2± 117.3 μm for the G[-] group, which was not significantly different from that for the G[+] group (533.4± 171.4 μm). The CRT in the G[-] and G[+] groups significantly reduced to 321.1± 114.6 μm and 347.8± 134.7 μm, respectively, at 1 month after the injection and to 360.4± 159.5 μm and 352.4± 151.9 μm, respectively, at 3 months after the injection (P< 0.01 for each group). The difference in the degree of CRT reduction between the two groups was not significant. Before treatment, the BCVA was 0.42± 0.32 logMAR units in the G[-] group and 0.57± 0.33 logMAR units in the G[+] group, showing no significant difference. The BCVA in the G[-] and G[+] groups improved significantly to 0.27± 0.26 logMAR units and 0.34± 0.42 logMAR units, respectively, at 1 month, and to 0.18± 0.20 logMAR units and 0.39± 0.34 logMAR units, respectively, at 3 months (P< 0.01). The BCVA in the G[-] group was significantly better than that in the G[+] group at 3 months (P=0.02).Conclusion: The therapeutic response of anti-VEGF agents for BRVO-ME is affected by the presence of glaucoma.Keywords: anti-vascular endothelial growth factor treatment, branch retinal vein occlusion, glaucoma, macular edema
Details
- Language :
- English
- ISSN :
- 11775483
- Volume :
- ume 16
- Database :
- Directory of Open Access Journals
- Journal :
- Clinical Ophthalmology
- Publication Type :
- Academic Journal
- Accession number :
- edsdoj.0db068224b1a4aa3a3045288be34ac2a
- Document Type :
- article